These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 21050557)

  • 1. [Efficacy and safety of natalizumab for multiple sclerosis and Crohn's disease: a meta analysis].
    Li YY; Li YP; Sun X; Wang L; Wen J; Cheng L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Oct; 32(5):533-42. PubMed ID: 21050557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
    Keeley KA; Rivey MP; Allington DR
    Ann Pharmacother; 2005 Nov; 39(11):1833-43. PubMed ID: 16219898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH; Bressler B
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis.
    Chandar AK; Singh S; Murad MH; Peyrin-Biroulet L; Loftus EV
    Inflamm Bowel Dis; 2015 Jul; 21(7):1695-708. PubMed ID: 25856769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab for active Crohn's disease.
    Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
    N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
    Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
    J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of natalizumab for formulary consideration.
    Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT
    Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease.
    Lin Z; Bai Y; Zheng P
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1100-10. PubMed ID: 21971373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
    Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Natalizumab in the treatment of multiple sclerosis].
    Horga A; Horga de la Parte JF
    Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
    O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M
    J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis: serious adverse events in Crohn's disease patients treated with TNF-alpha inhibitors.
    Zhang D; Xiong B; Li X; Xu T; Yu M
    Hepatogastroenterology; 2013 Sep; 60(126):1333-42. PubMed ID: 23340167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Meta-analysis of Shenmai injection treatment for acute myocardial infarction].
    Hu J; Zhang W; Xie YM; Wang LX; Nie XL; Zhang YL
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2760-7. PubMed ID: 23285929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of interferon-gamma-targeted therapy in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials.
    Cui D; Huang G; Yang D; Huang B; An B
    Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):507-13. PubMed ID: 23433962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab: bench to bedside and beyond.
    Rudick R; Polman C; Clifford D; Miller D; Steinman L
    JAMA Neurol; 2013 Feb; 70(2):172-82. PubMed ID: 23128399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical adverse effects of natalizumab: Protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails.
    Li H; Shi FH; Huang SY; Zhang SG; Gu ZC; Wei JF
    Medicine (Baltimore); 2018 Jul; 97(28):e11507. PubMed ID: 29995817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals.
    Juillerat P; Wasan SK; Fowler SA; Friedman S; Pabby VK; Coukas JA; Barto AE; Pellish R; Germansky KA; Cheifetz AS; Korzenik JR; Farraye FA; Yajnik V
    Inflamm Bowel Dis; 2013 Oct; 19(11):2457-63. PubMed ID: 23962896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis.
    Nikfar S; Rahimi R; Rezaie A; Abdollahi M
    Arch Med Sci; 2010 Apr; 6(2):236-44. PubMed ID: 22371753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab: overview of its pharmacology and safety.
    Baker DE
    Rev Gastroenterol Disord; 2007; 7(1):38-46. PubMed ID: 17392628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab in the treatment of pediatric multiple sclerosis.
    Talab R; Talabova M; Klzo L
    Neuro Endocrinol Lett; 2012; 33(6):579-89. PubMed ID: 23160229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.